ArticleEye (London, England)2026
Long-term clinical outcomes in chronic ocular graft-versus-host disease: a retrospective cohort study.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic ocular graft-versus-host disease (oGVHD) is a debilitating complication of allogeneic hematopoietic stem cell transplantation (HSCT) that leads to persistent ocular surface damage, visual morbidity, and substantial treatment burden. Despite its prevalence, long-term outcome data remain limited.
methodsWe conducted a retrospective cohort study of patients evaluated between 2012 and 2024 at a tertiary academic centre in Vancouver, Canada, with follow up of a year or more and recorded the outcomes of the first five years to characterise longitudinal ocular outcomes and therapeutic trajectories in patients with oGVHD.
resultsA total of 189 patients met inclusion criteria. At baseline, meibomian gland dysfunction (81.5%) and superficial punctate keratitis (49.7%) were highly prevalent. Over five years, these manifestations remained persistent in over half of patients, while vision-threatening complications including filamentary keratitis (3.7%), corneal neovascularisation (2.6%), and limbal stem cell deficiency (4.8%) emerged. Therapeutic escalation was common, with 92.1% of patients requiring artificial tears, 47.1% serum tears, 28.0% punctal cautery, 19.0% scleral lenses, and 7.4% topical cyclosporine by year five. Baseline NIH Eye Scores correlated with later complications and treatment intensity, while NIH Lung and Mouth Scores were also predictive of ocular surface disease.
conclusionsThese findings underscore the progressive, treatment-resistant nature of oGVHD and highlight the value of early ophthalmic referral and multidisciplinary management to preserve vision and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.